highlights of the day:central nervous system tumors
DESCRIPTION
Highlights of the Day:Central Nervous System Tumors. Presented By Michael Prados at 2014 ASCO Annual Meeting. Slide 2. Presented By Michael Prados at 2014 ASCO Annual Meeting. R9802 SCHEMA. Presented By Michael Prados at 2014 ASCO Annual Meeting. Data Maturity. - PowerPoint PPT PresentationTRANSCRIPT
Highlights of the Day:<br />Central Nervous System Tumors
Presented By Michael Prados at 2014 ASCO Annual Meeting
Slide 2
Presented By Michael Prados at 2014 ASCO Annual Meeting
R9802 SCHEMA
Presented By Michael Prados at 2014 ASCO Annual Meeting
Data Maturity
Presented By Michael Prados at 2014 ASCO Annual Meeting
Progression-Free Survival<br />ASCO 2014
Presented By Michael Prados at 2014 ASCO Annual Meeting
Overall Survival<br />ASCO 2014
Presented By Michael Prados at 2014 ASCO Annual Meeting
ASCO 2014: Overall Survival
Presented By Michael Prados at 2014 ASCO Annual Meeting
Cox Proportional Hazards Model for Overall Survival <br />(n=251)
Presented By Michael Prados at 2014 ASCO Annual Meeting
Conclusions (Prognostic Variables)
Presented By Michael Prados at 2014 ASCO Annual Meeting
Conclusions (Survival)<br />
Presented By Michael Prados at 2014 ASCO Annual Meeting
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779)/RT followed by CCI-779 versus chemo-irradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study.
Presented By Michael Prados at 2014 ASCO Annual Meeting
EORTC 26082/22081: Study Design
Presented By Michael Prados at 2014 ASCO Annual Meeting
EORTC 26082/22081: Overall survival
Presented By Michael Prados at 2014 ASCO Annual Meeting
Conclusions
Presented By Michael Prados at 2014 ASCO Annual Meeting
Correlation of Molecular Subtypes <br />with Survival in AVAglio
Presented By Michael Prados at 2014 ASCO Annual Meeting
Introduction
Presented By Michael Prados at 2014 ASCO Annual Meeting
AVAglio Trial Design and Primary Endpoints
Presented By Michael Prados at 2014 ASCO Annual Meeting
ITT and Biomarker-Evaluable Populations
Presented By Michael Prados at 2014 ASCO Annual Meeting
Background: Glioblastoma Gene Expression Subtypes
Presented By Michael Prados at 2014 ASCO Annual Meeting
Results: BEV Treatment Impacted PFS in Proneural and Mesenchymal Subtypes
Presented By Michael Prados at 2014 ASCO Annual Meeting
Results: BEV Effect on OS was Evident Only in the Proneural Subtype
Presented By Michael Prados at 2014 ASCO Annual Meeting
Results: Effect of BEV on OS was Significant in Univariate and Multivariate Analyses
Presented By Michael Prados at 2014 ASCO Annual Meeting
Conclusions
Presented By Michael Prados at 2014 ASCO Annual Meeting